BMS, Pfizer secure victory over generic makers

In a victory for Bristol-Myers Squibb (BMS) and Pfizer, a US federal judge has affirmed patents covering blood-thinner Eliquis (apixaban).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Generics

Sigmapharm to appeal Pfizer and BMS’ Eliquis win

3 September 2020 Generics maker Sigmapharm Laboratories is appealing against a court win for Pfizer and Bristol Myers Squibb over patents for blood-thinner Eliquis.

Biotechnology

Pfizer to collaborate with Imcyse on new immunotherapy programme

5 February 2021 Pfizer has struck a research and licensing agreement with Belgium biopharmaceutical company Imcyse to develop treatments for rheumatoid arthritis using Imotopes - Imcyse’s platform of immunotherapeutics based on synthetic peptides.

Americas

BMS, Pfizer win patent dispute over blockbuster drug, Eliquis

6 September 2021 In a victory for Bristol-Myers Squibb and Pfizer, the US Court of Appeals for the Federal Circuit has affirmed the validity of a pair of patents covering blood clot treatment, Eliquis.

More on this story

Generics

Sigmapharm to appeal Pfizer and BMS’ Eliquis win

3 September 2020 Generics maker Sigmapharm Laboratories is appealing against a court win for Pfizer and Bristol Myers Squibb over patents for blood-thinner Eliquis.

Biotechnology

Pfizer to collaborate with Imcyse on new immunotherapy programme

Americas

BMS, Pfizer win patent dispute over blockbuster drug, Eliquis

More on this story

Generics

Sigmapharm to appeal Pfizer and BMS’ Eliquis win

3 September 2020 Generics maker Sigmapharm Laboratories is appealing against a court win for Pfizer and Bristol Myers Squibb over patents for blood-thinner Eliquis.

Biotechnology

Pfizer to collaborate with Imcyse on new immunotherapy programme

Americas

BMS, Pfizer win patent dispute over blockbuster drug, Eliquis